English
简体中文
Total: £ 56.28
Published Date: 2026-04-07 | Pages: 120 | Tables: 127 | Medical Devices & Consumables
The global Devices for Inhaled Medications market was valued at US$ 3500 million in 2025 and is anticipated to reach US$ 5390 million by 2032, at a CAGR of 6.0% from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Devices for Inhaled Medications competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Devices for inhaled medications are medical device systems that deliver drugs directly to the lungs or nasal cavity through the respiratory tract, including pressurized metered-dose inhalers (pMDI), dry powder inhalers (DPI), soft mist inhalers (SMI), and nebulizers as core device types. The industry encompasses device design and manufacturing, drug-device co-development, precision drug delivery control systems, and related intelligent monitoring components, serving as the key technical carrier for respiratory disease treatment. From the industry chain perspective, the upstream involves core components such as precision molds, polymer materials, and sensor chips; the midstream covers device integration manufacturing and drug-device combination product development; the downstream extends to patient use training, data monitoring services, and personalized treatment regimen management. As the prevalence of chronic respiratory diseases rises, demand for precision medicine grows, and environmental sustainability requirements tighten, inhaled medication devices are undergoing a profound transformation from traditional mechanical devices toward intelligent, low-carbon, and personalized directions, with technical barriers manifested in multi-dimensional innovations including fluid mechanics design, particle engineering, human-machine interaction optimization, and environmentally friendly propellant substitution.
Market Development Opportunities & Main Driving Factors
The global patient base for asthma and COPD continues to expand. AstraZeneca's AIRSUPRA received FDA approval in January 2023 as the first anti-inflammatory rescue inhaler, while Verona Pharma's ensifentrine was approved in June 2024 as the first new-mechanism COPD drug in over two decades. Teva launched the first digital inhaler GoResp Digihaler in July 2023, and AstraZeneca selected the Hailie platform for clinical trials in May 2024, making intelligence and digitalization core trends. The EU implemented the F-gas regulation in February 2024, requiring quota allocation and fee imposition on inhaler propellants from 2025 onward, accelerating industry low-carbon transformation.
Market Challenges and Risks
The EU ECHA's draft PFAS control regulation, if implemented, would ban key propellants, creating policy conflict with current low-carbon pathways. GSK's low-carbon Ventolin will not reach the market until after 2026, showing a transition cycle of 3-5 years. The FTC issued warnings to Novartis, Teva and other companies in May 2025, challenging over 200 device patents and threatening branded drug market exclusivity. Teva announced the discontinuation of its Digihaler product line in June 2024, reflecting the commercial setback of digital inhaler devices.
Downstream Demand Trends
The GINA 2023 guidelines support anti-inflammatory plus bronchodilator combination rescue regimens, driving devices toward multi-functional upgrades. Nemera launched a pediatric-specific multi-dose dry powder inhaler in November 2023, emphasizing compliance optimization. The UK NHS's Re-Hale recycling program avoided approximately 176 tons of CO2 emissions during 2023-2024, reflecting the healthcare system's quantified environmental footprint management needs. Changfeng Pharmaceutical submitted its Hong Kong IPO application in January 2024, planning MDI production by 2026, demonstrating Chinese companies' leap from technology following to production autonomy.
Regional Trends
Europe, leveraging its leading precision manufacturing clusters and the MDR regulatory framework, continues to dominate innovation in inhalation devices, while the F-gas regulation is accelerating the industry's transition toward low-carbon technologies. The North American market, benefiting from a mature reimbursement system and the FDA's openness to digital therapeutics, leads the commercial application of smart inhalers. The Asia-Pacific region exhibits the most dynamic growth, with Chinese local enterprises transitioning from technology followers to self-sufficient manufacturers, while India and Southeast Asia leverage their cost advantages to become major OEM hubs. In Latin America, the Middle East, and Africa, rising healthcare expenditures and improved chronic disease management are gradually releasing price-sensitive demand, forming emerging incremental markets.
This report delivers a comprehensive overview of the global Devices for Inhaled Medications market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Devices for Inhaled Medications. The Devices for Inhaled Medications market size, estimates, and forecasts are provided in terms of sales volume (Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Devices for Inhaled Medications market comprehensively. Regional market sizes by Type, by Application, by Actuation Mechanism, and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Devices for Inhaled Medications manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
AstraZeneca
Aptar Pharma
Nemera
Boehringer Ingelheim
Cipla
Catalent
Chiesi
Hovione
Iconovo
Bespak
GSK
Vectura
Kindeva
Novartis
Segment by Type
Dry Powder Inhalers
Nebulizer
Nasal Inhalers
Vaporized Inhalers
Segment by Actuation Mechanism
Mechanical Spring Driven
Pneumatic Driven
Ultrasonic Driven
Electric Driven
Segment by Dose Metering
Metered Dose Devices
Continuous Devices
Segment by Reusability
Single Use Devices
Refillable Devices
by Application
Asthma
Chronic Obstructive Pulmonary Disease
Cystic Fibrosis
Pulmonary Arterial Hypertension
Vaccine Delivery
Consumption by Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
India
Malaysia
Vietnam
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by Actuation Mechanism, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Devices for Inhaled Medications manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Devices for Inhaled Medications sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Devices for Inhaled Medications Market Overview
1.1 Product Definition
1.2 Devices for Inhaled Medications by Type
1.2.1 Global Devices for Inhaled Medications Market Value by Type: 2025 vs 2032
1.2.2 Dry Powder Inhalers
1.2.3 Nebulizer
1.2.4 Nasal Inhalers
1.2.5 Vaporized Inhalers
1.3 Devices for Inhaled Medications by Actuation Mechanism
1.3.1 Global Devices for Inhaled Medications Market Value by Actuation Mechanism: 2025 vs 2032
1.3.2 Mechanical Spring Driven
1.3.3 Pneumatic Driven
1.3.4 Ultrasonic Driven
1.3.5 Electric Driven
1.4 Devices for Inhaled Medications by Dose Metering
1.4.1 Global Devices for Inhaled Medications Market Value by Dose Metering: 2025 vs 2032
1.4.2 Metered Dose Devices
1.4.3 Continuous Devices
1.5 Devices for Inhaled Medications by Reusability
1.5.1 Global Devices for Inhaled Medications Market Value by Reusability: 2025 vs 2032
1.5.2 Single Use Devices
1.5.3 Refillable Devices
1.6 Devices for Inhaled Medications by Application
1.6.1 Global Devices for Inhaled Medications Market Value by Application: 2025 vs 2032
1.6.2 Asthma
1.6.3 Chronic Obstructive Pulmonary Disease
1.6.4 Cystic Fibrosis
1.6.5 Pulmonary Arterial Hypertension
1.6.6 Vaccine Delivery
1.7 Global Devices for Inhaled Medications Market Size Estimates and Forecasts
1.7.1 Global Devices for Inhaled Medications Revenue 2021–2032
1.7.2 Global Devices for Inhaled Medications Sales 2021–2032
1.7.3 Global Devices for Inhaled Medications Market Average Price (2021–2032)
1.8 Assumptions and Limitations
2 Devices for Inhaled Medications Market Competition by Manufacturers
2.1 Global Devices for Inhaled Medications Sales Market Share by Manufacturers (2021–2026)
2.2 Global Devices for Inhaled Medications Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Devices for Inhaled Medications Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Devices for Inhaled Medications, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Devices for Inhaled Medications, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Devices for Inhaled Medications, Product Types and Applications
2.7 Global Key Manufacturers of Devices for Inhaled Medications, Date of Entry into the Industry
2.8 Global Devices for Inhaled Medications Market Competitive Situation and Trends
2.8.1 Global Devices for Inhaled Medications Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Devices for Inhaled Medications Players Market Share by Revenue
2.8.3 Global Devices for Inhaled Medications Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Devices for Inhaled Medications Market Scenario by Region
3.1 Global Devices for Inhaled Medications Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Devices for Inhaled Medications Sales by Region: 2021–2032
3.2.1 Global Devices for Inhaled Medications Sales by Region: 2021–2026
3.2.2 Global Devices for Inhaled Medications Sales by Region: 2027–2032
3.3 Global Devices for Inhaled Medications Revenue by Region: 2021–2032
3.3.1 Global Devices for Inhaled Medications Revenue by Region: 2021–2026
3.3.2 Global Devices for Inhaled Medications Revenue by Region: 2027–2032
3.4 North America Devices for Inhaled Medications Market Facts & Figures by Country
3.4.1 North America Devices for Inhaled Medications Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Devices for Inhaled Medications Sales by Country (2021–2032)
3.4.3 North America Devices for Inhaled Medications Revenue by Country (2021–2032)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Devices for Inhaled Medications Market Facts & Figures by Country
3.5.1 Europe Devices for Inhaled Medications Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Devices for Inhaled Medications Sales by Country (2021–2032)
3.5.3 Europe Devices for Inhaled Medications Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Devices for Inhaled Medications Market Facts & Figures by Region
3.6.1 Asia Pacific Devices for Inhaled Medications Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Devices for Inhaled Medications Sales by Region (2021–2032)
3.6.3 Asia Pacific Devices for Inhaled Medications Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Malaysia
3.6.9 Vietnam
3.7 Latin America Devices for Inhaled Medications Market Facts & Figures by Country
3.7.1 Latin America Devices for Inhaled Medications Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Devices for Inhaled Medications Sales by Country (2021–2032)
3.7.3 Latin America Devices for Inhaled Medications Revenue by Country (2021–2032)
3.7.4 Brazil
3.7.5 Argentina
3.8 Middle East and Africa Devices for Inhaled Medications Market Facts & Figures by Country
3.8.1 Middle East and Africa Devices for Inhaled Medications Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Devices for Inhaled Medications Sales by Country (2021–2032)
3.8.3 Middle East and Africa Devices for Inhaled Medications Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Devices for Inhaled Medications Sales by Type (2021–2032)
4.1.1 Global Devices for Inhaled Medications Sales by Type (2021–2026)
4.1.2 Global Devices for Inhaled Medications Sales by Type (2027–2032)
4.1.3 Global Devices for Inhaled Medications Sales Market Share by Type (2021–2032)
4.2 Global Devices for Inhaled Medications Revenue by Type (2021–2032)
4.2.1 Global Devices for Inhaled Medications Revenue by Type (2021–2026)
4.2.2 Global Devices for Inhaled Medications Revenue by Type (2027–2032)
4.2.3 Global Devices for Inhaled Medications Revenue Market Share by Type (2021–2032)
4.3 Global Devices for Inhaled Medications Price by Type (2021–2032)
5 Segment by Application
5.1 Global Devices for Inhaled Medications Sales by Application (2021–2032)
5.1.1 Global Devices for Inhaled Medications Sales by Application (2021–2026)
5.1.2 Global Devices for Inhaled Medications Sales by Application (2027–2032)
5.1.3 Global Devices for Inhaled Medications Sales Market Share by Application (2021–2032)
5.2 Global Devices for Inhaled Medications Revenue by Application (2021–2032)
5.2.1 Global Devices for Inhaled Medications Revenue by Application (2021–2026)
5.2.2 Global Devices for Inhaled Medications Revenue by Application (2027–2032)
5.2.3 Global Devices for Inhaled Medications Revenue Market Share by Application (2021–2032)
5.3 Global Devices for Inhaled Medications Price by Application (2021–2032)
6 Key Companies Profiled
6.1 AstraZeneca
6.1.1 AstraZeneca Company Information
6.1.2 AstraZeneca Description and Business Overview
6.1.3 AstraZeneca Devices for Inhaled Medications Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 AstraZeneca Devices for Inhaled Medications Product Portfolio
6.1.5 AstraZeneca Recent Developments/Updates
6.2 Aptar Pharma
6.2.1 Aptar Pharma Company Information
6.2.2 Aptar Pharma Description and Business Overview
6.2.3 Aptar Pharma Devices for Inhaled Medications Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Aptar Pharma Devices for Inhaled Medications Product Portfolio
6.2.5 Aptar Pharma Recent Developments/Updates
6.3 Nemera
6.3.1 Nemera Company Information
6.3.2 Nemera Description and Business Overview
6.3.3 Nemera Devices for Inhaled Medications Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Nemera Devices for Inhaled Medications Product Portfolio
6.3.5 Nemera Recent Developments/Updates
6.4 Boehringer Ingelheim
6.4.1 Boehringer Ingelheim Company Information
6.4.2 Boehringer Ingelheim Description and Business Overview
6.4.3 Boehringer Ingelheim Devices for Inhaled Medications Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Boehringer Ingelheim Devices for Inhaled Medications Product Portfolio
6.4.5 Boehringer Ingelheim Recent Developments/Updates
6.5 Cipla
6.5.1 Cipla Company Information
6.5.2 Cipla Description and Business Overview
6.5.3 Cipla Devices for Inhaled Medications Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Cipla Devices for Inhaled Medications Product Portfolio
6.5.5 Cipla Recent Developments/Updates
6.6 Catalent
6.6.1 Catalent Company Information
6.6.2 Catalent Description and Business Overview
6.6.3 Catalent Devices for Inhaled Medications Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Catalent Devices for Inhaled Medications Product Portfolio
6.6.5 Catalent Recent Developments/Updates
6.7 Chiesi
6.7.1 Chiesi Company Information
6.7.2 Chiesi Description and Business Overview
6.7.3 Chiesi Devices for Inhaled Medications Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Chiesi Devices for Inhaled Medications Product Portfolio
6.7.5 Chiesi Recent Developments/Updates
6.8 Hovione
6.8.1 Hovione Company Information
6.8.2 Hovione Description and Business Overview
6.8.3 Hovione Devices for Inhaled Medications Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Hovione Devices for Inhaled Medications Product Portfolio
6.8.5 Hovione Recent Developments/Updates
6.9 Iconovo
6.9.1 Iconovo Company Information
6.9.2 Iconovo Description and Business Overview
6.9.3 Iconovo Devices for Inhaled Medications Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Iconovo Devices for Inhaled Medications Product Portfolio
6.9.5 Iconovo Recent Developments/Updates
6.10 Bespak
6.10.1 Bespak Company Information
6.10.2 Bespak Description and Business Overview
6.10.3 Bespak Devices for Inhaled Medications Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Bespak Devices for Inhaled Medications Product Portfolio
6.10.5 Bespak Recent Developments/Updates
6.11 GSK
6.11.1 GSK Company Information
6.11.2 GSK Description and Business Overview
6.11.3 GSK Devices for Inhaled Medications Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 GSK Devices for Inhaled Medications Product Portfolio
6.11.5 GSK Recent Developments/Updates
6.12 Vectura
6.12.1 Vectura Company Information
6.12.2 Vectura Description and Business Overview
6.12.3 Vectura Devices for Inhaled Medications Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 Vectura Devices for Inhaled Medications Product Portfolio
6.12.5 Vectura Recent Developments/Updates
6.13 Kindeva
6.13.1 Kindeva Company Information
6.13.2 Kindeva Description and Business Overview
6.13.3 Kindeva Devices for Inhaled Medications Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 Kindeva Devices for Inhaled Medications Product Portfolio
6.13.5 Kindeva Recent Developments/Updates
6.14 Novartis
6.14.1 Novartis Company Information
6.14.2 Novartis Description and Business Overview
6.14.3 Novartis Devices for Inhaled Medications Sales, Revenue, and Gross Margin (2021–2026)
6.14.4 Novartis Devices for Inhaled Medications Product Portfolio
6.14.5 Novartis Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Devices for Inhaled Medications Industry Chain Analysis
7.2 Devices for Inhaled Medications Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Devices for Inhaled Medications Production Mode & Process Analysis
7.4 Devices for Inhaled Medications Sales and Marketing
7.4.1 Devices for Inhaled Medications Sales Channels
7.4.2 Devices for Inhaled Medications Distributors
7.5 Devices for Inhaled Medications Customer Analysis
8 Devices for Inhaled Medications Market Dynamics
8.1 Devices for Inhaled Medications Industry Trends
8.2 Devices for Inhaled Medications Market Drivers
8.3 Devices for Inhaled Medications Market Challenges
8.4 Devices for Inhaled Medications Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Devices for Inhaled Medications Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Devices for Inhaled Medications Market Value by Actuation Mechanism (US$ Million), 2025 vs 2032
Table 3. Global Devices for Inhaled Medications Market Value by Dose Metering (US$ Million), 2025 vs 2032
Table 4. Global Devices for Inhaled Medications Market Value by Reusability (US$ Million), 2025 vs 2032
Table 5. Global Devices for Inhaled Medications Market Value by Application (US$ Million), 2025 vs 2032
Table 6. Global Devices for Inhaled Medications Market Competitive Situation by Manufacturers in 2025
Table 7. Global Devices for Inhaled Medications Sales (Units) of Key Manufacturers (2021–2026)
Table 8. Global Devices for Inhaled Medications Sales Market Share by Manufacturers (2021–2026)
Table 9. Global Devices for Inhaled Medications Revenue (US$ Million) by Manufacturers (2021–2026)
Table 10. Global Devices for Inhaled Medications Revenue Share by Manufacturers (2021–2026)
Table 11. Global Market Devices for Inhaled Medications Average Price (USD/Unit) of Key Manufacturers (2021–2026)
Table 12. Global Key Players of Devices for Inhaled Medications, Industry Ranking, 2023 vs 2024 vs 2025
Table 13. Global Key Manufacturers of Devices for Inhaled Medications, Manufacturing Sites and Headquarters
Table 14. Global Key Manufacturers of Devices for Inhaled Medications, Product Types and Applications
Table 15. Global Key Manufacturers of Devices for Inhaled Medications, Date of Entry into the Industry
Table 16. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 17. Global Devices for Inhaled Medications Companies by Tier (Tier 1, Tier 2, Tier 3), based on Devices for Inhaled Medications Revenue, 2025
Table 18. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 19. Global Devices for Inhaled Medications Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 20. Global Devices for Inhaled Medications Sales by Region (Units), 2021–2026
Table 21. Global Devices for Inhaled Medications Sales Market Share by Region (2021–2026)
Table 22. Global Devices for Inhaled Medications Sales by Region (Units), 2027–2032
Table 23. Global Devices for Inhaled Medications Sales Market Share by Region (2027–2032)
Table 24. Global Devices for Inhaled Medications Revenue by Region (US$ Million), 2021–2026
Table 25. Global Devices for Inhaled Medications Revenue Market Share by Region (2021–2026)
Table 26. Global Devices for Inhaled Medications Revenue by Region (US$ Million), 2027–2032
Table 27. Global Devices for Inhaled Medications Revenue Market Share by Region (2027–2032)
Table 28. North America Devices for Inhaled Medications Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 29. North America Devices for Inhaled Medications Sales by Country (Units), 2021–2026
Table 30. North America Devices for Inhaled Medications Sales by Country (Units), 2027–2032
Table 31. North America Devices for Inhaled Medications Revenue by Country (US$ Million), 2021–2026
Table 32. North America Devices for Inhaled Medications Revenue by Country (US$ Million), 2027–2032
Table 33. Europe Devices for Inhaled Medications Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 34. Europe Devices for Inhaled Medications Sales by Country (Units), 2021–2026
Table 35. Europe Devices for Inhaled Medications Sales by Country (Units), 2027–2032
Table 36. Europe Devices for Inhaled Medications Revenue by Country (US$ Million), 2021–2026
Table 37. Europe Devices for Inhaled Medications Revenue by Country (US$ Million), 2027–2032
Table 38. Asia Pacific Devices for Inhaled Medications Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 39. Asia Pacific Devices for Inhaled Medications Sales by Region (Units), 2021–2026
Table 40. Asia Pacific Devices for Inhaled Medications Sales by Region (Units), 2027–2032
Table 41. Asia Pacific Devices for Inhaled Medications Revenue by Region (US$ Million), 2021–2026
Table 42. Asia Pacific Devices for Inhaled Medications Revenue by Region (US$ Million), 2027–2032
Table 43. Latin America Devices for Inhaled Medications Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 44. Latin America Devices for Inhaled Medications Sales by Country (Units), 2021–2026
Table 45. Latin America Devices for Inhaled Medications Sales by Country (Units), 2027–2032
Table 46. Latin America Devices for Inhaled Medications Revenue by Country (US$ Million), 2021–2026
Table 47. Latin America Devices for Inhaled Medications Revenue by Country (US$ Million), 2027–2032
Table 48. Middle East and Africa Devices for Inhaled Medications Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 49. Middle East and Africa Devices for Inhaled Medications Sales by Country (Units), 2021–2026
Table 50. Middle East and Africa Devices for Inhaled Medications Sales by Country (Units), 2027–2032
Table 51. Middle East and Africa Devices for Inhaled Medications Revenue by Country (US$ Million), 2021–2026
Table 52. Middle East and Africa Devices for Inhaled Medications Revenue by Country (US$ Million), 2027–2032
Table 53. Global Devices for Inhaled Medications Sales (Units) by Type (2021–2026)
Table 54. Global Devices for Inhaled Medications Sales (Units) by Type (2027–2032)
Table 55. Global Devices for Inhaled Medications Sales Market Share by Type (2021–2026)
Table 56. Global Devices for Inhaled Medications Sales Market Share by Type (2027–2032)
Table 57. Global Devices for Inhaled Medications Revenue (US$ Million) by Type (2021–2026)
Table 58. Global Devices for Inhaled Medications Revenue (US$ Million) by Type (2027–2032)
Table 59. Global Devices for Inhaled Medications Revenue Market Share by Type (2021–2026)
Table 60. Global Devices for Inhaled Medications Revenue Market Share by Type (2027–2032)
Table 61. Global Devices for Inhaled Medications Price (USD/Unit) by Type (2021–2026)
Table 62. Global Devices for Inhaled Medications Price (USD/Unit) by Type (2027–2032)
Table 63. Global Devices for Inhaled Medications Sales (Units) by Application (2021–2026)
Table 64. Global Devices for Inhaled Medications Sales (Units) by Application (2027–2032)
Table 65. Global Devices for Inhaled Medications Sales Market Share by Application (2021–2026)
Table 66. Global Devices for Inhaled Medications Sales Market Share by Application (2027–2032)
Table 67. Global Devices for Inhaled Medications Revenue (US$ Million) by Application (2021–2026)
Table 68. Global Devices for Inhaled Medications Revenue (US$ Million) by Application (2027–2032)
Table 69. Global Devices for Inhaled Medications Revenue Market Share by Application (2021–2026)
Table 70. Global Devices for Inhaled Medications Revenue Market Share by Application (2027–2032)
Table 71. Global Devices for Inhaled Medications Price (USD/Unit) by Application (2021–2026)
Table 72. Global Devices for Inhaled Medications Price (USD/Unit) by Application (2027–2032)
Table 73. AstraZeneca Company Information
Table 74. AstraZeneca Description and Business Overview
Table 75. AstraZeneca Devices for Inhaled Medications Sales (Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 76. AstraZeneca Devices for Inhaled Medications Product
Table 77. AstraZeneca Recent Developments/Updates
Table 78. Aptar Pharma Company Information
Table 79. Aptar Pharma Description and Business Overview
Table 80. Aptar Pharma Devices for Inhaled Medications Sales (Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 81. Aptar Pharma Devices for Inhaled Medications Product
Table 82. Aptar Pharma Recent Developments/Updates
Table 83. Nemera Company Information
Table 84. Nemera Description and Business Overview
Table 85. Nemera Devices for Inhaled Medications Sales (Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 86. Nemera Devices for Inhaled Medications Product
Table 87. Nemera Recent Developments/Updates
Table 88. Boehringer Ingelheim Company Information
Table 89. Boehringer Ingelheim Description and Business Overview
Table 90. Boehringer Ingelheim Devices for Inhaled Medications Sales (Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 91. Boehringer Ingelheim Devices for Inhaled Medications Product
Table 92. Boehringer Ingelheim Recent Developments/Updates
Table 93. Cipla Company Information
Table 94. Cipla Description and Business Overview
Table 95. Cipla Devices for Inhaled Medications Sales (Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 96. Cipla Devices for Inhaled Medications Product
Table 97. Cipla Recent Developments/Updates
Table 98. Catalent Company Information
Table 99. Catalent Description and Business Overview
Table 100. Catalent Devices for Inhaled Medications Sales (Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 101. Catalent Devices for Inhaled Medications Product
Table 102. Catalent Recent Developments/Updates
Table 103. Chiesi Company Information
Table 104. Chiesi Description and Business Overview
Table 105. Chiesi Devices for Inhaled Medications Sales (Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 106. Chiesi Devices for Inhaled Medications Product
Table 107. Chiesi Recent Developments/Updates
Table 108. Hovione Company Information
Table 109. Hovione Description and Business Overview
Table 110. Hovione Devices for Inhaled Medications Sales (Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 111. Hovione Devices for Inhaled Medications Product
Table 112. Hovione Recent Developments/Updates
Table 113. Iconovo Company Information
Table 114. Iconovo Description and Business Overview
Table 115. Iconovo Devices for Inhaled Medications Sales (Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 116. Iconovo Devices for Inhaled Medications Product
Table 117. Iconovo Recent Developments/Updates
Table 118. Bespak Company Information
Table 119. Bespak Description and Business Overview
Table 120. Bespak Devices for Inhaled Medications Sales (Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 121. Bespak Devices for Inhaled Medications Product
Table 122. Bespak Recent Developments/Updates
Table 123. GSK Company Information
Table 124. GSK Description and Business Overview
Table 125. GSK Devices for Inhaled Medications Sales (Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 126. GSK Devices for Inhaled Medications Product
Table 127. GSK Recent Developments/Updates
Table 128. Vectura Company Information
Table 129. Vectura Description and Business Overview
Table 130. Vectura Devices for Inhaled Medications Sales (Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 131. Vectura Devices for Inhaled Medications Product
Table 132. Vectura Recent Developments/Updates
Table 133. Kindeva Company Information
Table 134. Kindeva Description and Business Overview
Table 135. Kindeva Devices for Inhaled Medications Sales (Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 136. Kindeva Devices for Inhaled Medications Product
Table 137. Kindeva Recent Developments/Updates
Table 138. Novartis Company Information
Table 139. Novartis Description and Business Overview
Table 140. Novartis Devices for Inhaled Medications Sales (Units), Revenue (US$ Million), Price (USD/Unit), and Gross Margin (2021–2026)
Table 141. Novartis Devices for Inhaled Medications Product
Table 142. Novartis Recent Developments/Updates
Table 143. Key Raw Materials Lists
Table 144. Raw Materials Key Suppliers Lists
Table 145. Devices for Inhaled Medications Distributors List
Table 146. Devices for Inhaled Medications Customers List
Table 147. Devices for Inhaled Medications Market Trends
Table 148. Devices for Inhaled Medications Market Drivers
Table 149. Devices for Inhaled Medications Market Challenges
Table 150. Devices for Inhaled Medications Market Restraints
Table 151. Research Programs/Design for This Report
Table 152. Key Data Information from Secondary Sources
Table 153. Key Data Information from Primary Sources
Table 154. Authors List of This Report
List of Figures
Figure 1. Product Picture of Devices for Inhaled Medications
Figure 2. Global Devices for Inhaled Medications Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Devices for Inhaled Medications Market Share by Type: 2025 & 2032
Figure 4. Dry Powder Inhalers Product Picture
Figure 5. Nebulizer Product Picture
Figure 6. Nasal Inhalers Product Picture
Figure 7. Vaporized Inhalers Product Picture
Figure 8. Global Devices for Inhaled Medications Market Value by Actuation Mechanism (US$ Million), 2021–2032
Figure 9. Global Devices for Inhaled Medications Market Share by Actuation Mechanism: 2025 vs 2032
Figure 10. Mechanical Spring Driven Product Picture
Figure 11. Pneumatic Driven Product Picture
Figure 12. Ultrasonic Driven Product Picture
Figure 13. Electric Driven Product Picture
Figure 14. Global Devices for Inhaled Medications Market Value by Dose Metering (US$ Million), 2021–2032
Figure 15. Global Devices for Inhaled Medications Market Share by Dose Metering: 2025 vs 2032
Figure 16. Metered Dose Devices Product Picture
Figure 17. Continuous Devices Product Picture
Figure 18. Global Devices for Inhaled Medications Market Value by Reusability (US$ Million), 2021–2032
Figure 19. Global Devices for Inhaled Medications Market Share by Reusability: 2025 vs 2032
Figure 20. Single Use Devices Product Picture
Figure 21. Refillable Devices Product Picture
Figure 22. Global Devices for Inhaled Medications Market Value by Application (US$ Million), 2021–2032
Figure 23. Global Devices for Inhaled Medications Market Share by Application: 2025 & 2032
Figure 24. Asthma
Figure 25. Chronic Obstructive Pulmonary Disease
Figure 26. Cystic Fibrosis
Figure 27. Pulmonary Arterial Hypertension
Figure 28. Vaccine Delivery
Figure 29. Global Devices for Inhaled Medications Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 30. Global Devices for Inhaled Medications Market Size (US$ Million), 2021–2032
Figure 31. Global Devices for Inhaled Medications Sales (Units), 2021–2032
Figure 32. Global Devices for Inhaled Medications Average Price (USD/Unit), 2021–2032
Figure 33. Devices for Inhaled Medications Report Years Considered
Figure 34. Devices for Inhaled Medications Sales Share by Manufacturers in 2025
Figure 35. Global Devices for Inhaled Medications Revenue Share by Manufacturers in 2025
Figure 36. Top 5 and Top 10 Global Devices for Inhaled Medications Players: Market Share by Revenue in Devices for Inhaled Medications in 2025
Figure 37. Devices for Inhaled Medications Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 38. Global Devices for Inhaled Medications Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 39. North America Devices for Inhaled Medications Sales Market Share by Country (2021–2032)
Figure 40. North America Devices for Inhaled Medications Revenue Market Share by Country (2021–2032)
Figure 41. U.S. Devices for Inhaled Medications Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. Canada Devices for Inhaled Medications Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Europe Devices for Inhaled Medications Sales Market Share by Country (2021–2032)
Figure 44. Europe Devices for Inhaled Medications Revenue Market Share by Country (2021–2032)
Figure 45. Germany Devices for Inhaled Medications Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. France Devices for Inhaled Medications Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. U.K. Devices for Inhaled Medications Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Italy Devices for Inhaled Medications Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Russia Devices for Inhaled Medications Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Asia Pacific Devices for Inhaled Medications Sales Market Share by Region (2021–2032)
Figure 51. Asia Pacific Devices for Inhaled Medications Revenue Market Share by Region (2021–2032)
Figure 52. China Devices for Inhaled Medications Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. Japan Devices for Inhaled Medications Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. South Korea Devices for Inhaled Medications Revenue Growth Rate (US$ Million), 2021–2032
Figure 55. India Devices for Inhaled Medications Revenue Growth Rate (US$ Million), 2021–2032
Figure 56. Malaysia Devices for Inhaled Medications Revenue Growth Rate (US$ Million), 2021–2032
Figure 57. Vietnam Devices for Inhaled Medications Revenue Growth Rate (US$ Million), 2021–2032
Figure 58. Latin America Devices for Inhaled Medications Sales Market Share by Country (2021–2032)
Figure 59. Latin America Devices for Inhaled Medications Revenue Market Share by Country (2021–2032)
Figure 60. Brazil Devices for Inhaled Medications Revenue Growth Rate (US$ Million), 2021–2032
Figure 61. Argentina Devices for Inhaled Medications Revenue Growth Rate (US$ Million), 2021–2032
Figure 62. Middle East and Africa Devices for Inhaled Medications Sales Market Share by Country (2021–2032)
Figure 63. Middle East and Africa Devices for Inhaled Medications Revenue Market Share by Country (2021–2032)
Figure 64. Turkey Devices for Inhaled Medications Revenue Growth Rate (US$ Million), 2021–2032
Figure 65. Saudi Arabia Devices for Inhaled Medications Revenue Growth Rate (US$ Million), 2021–2032
Figure 66. U.A.E Devices for Inhaled Medications Revenue Growth Rate (US$ Million), 2021–2032
Figure 67. Global Sales Market Share of Devices for Inhaled Medications by Type (2021–2032)
Figure 68. Global Revenue Market Share of Devices for Inhaled Medications by Type (2021–2032)
Figure 69. Global Devices for Inhaled Medications Price (USD/Unit) by Type (2021–2032)
Figure 70. Global Sales Market Share of Devices for Inhaled Medications by Application (2021–2032)
Figure 71. Global Revenue Market Share of Devices for Inhaled Medications by Application (2021–2032)
Figure 72. Global Devices for Inhaled Medications Price (USD/Unit) by Application (2021–2032)
Figure 73. Devices for Inhaled Medications Value Chain
Figure 74. Channels of Distribution (Direct Vs Distribution)
Figure 75. Bottom-up and Top-down Approaches for This Report
Figure 76. Data Triangulation
Figure 77. Key Executives Interviewed
